Key Takeaways
- 71% of healthcare organizations that have reported measurable AI value are not rapidly expanding their AI initiatives.
- EHR integration difficulty is now the leading barrier to AI adoption, cited by 44% of respondents, ahead of clinician trust and regulatory concerns.
- 92% of survey respondents say clinical domain expertise is critical when evaluating an AI vendor.
- Deloitte's 2026 State of AI found 74% of organizations want AI to grow revenue but only 20% have seen it happen.
- One in four healthcare organizations is attempting to adopt AI with no clearly defined owner of that strategy.
Healthcare AI has produced no shortage of successful pilot projects. The question the industry is now wrestling with is different: why do so many of those pilots break down when deployed to the production environment?
A new survey from Carta Healthcare, found that 71 percent of healthcare organizations that have seen measurable value from AI are still not expanding those initiatives rapidly. The pilots worked, but the initiative failed when deployed into the larger operational environment.
Why Pilots Succeed, and Scale Fails
Pilot projects succeed for specific reasons that are difficult to replicate in production. They have a committed champion, a clearly defined workflow, and concentrated organizational attention. When organizations attempt to spread those conditions across departments, each of those advantages disappears.
Deloitte's 2026 State of AI survey, conducted with 3,235 directors and C-suite leaders across 24 countries, found that 74% of organizations want AI to grow revenue but only 20% have seen it happen. McKinsey's State of AI 2025 report found that 88% of organizations use AI in at least one function, but only 6% qualify as high performers who can attribute meaningful business impact to it. Both findings describe the same phenomenon: adoption is not the problem. Operationalization is.
The organizations stuck in pilot mode share a common pattern. They built a capable system, but they didn’t build the operational infrastructure around it. No integration owner. No defined workflow redesign. No measurement framework that could survive the transition from a controlled setting to a fragmented clinical environment. The technology was ready; the organization was not.
Gartner predicts over 40% of agentic AI projects will be canceled by the end of 2027 due to escalating costs, unclear business value, and inadequate risk controls. In healthcare, those three failure modes map directly to what the Carta survey identifies: the cost of failed integration, the absence of measurable outcomes, and governance structures that were never built.
For health systems navigating this pattern, Taazaa's breakdown of healthcare AI technology adoption challenges covers the structural barriers that consistently separate successful deployments from stalled ones.
The Integration Problem
The 44% of respondents in the Carta survey found that difficulty with EHR integration is now the leading barrier to AI adoption. That places it well ahead of clinician trust (26%) and regulatory concerns (26%).
The finding reflects where AI ultimately succeeds or fails: inside clinicians' existing workflows. A tool can be accurate in a demo and still fail the moment a clinician has to step out of their workflow to use it. Added steps are where adoption dies.
The integration problem is not purely technical. Clinical documentation is often inconsistent and highly contextual. Extracting meaningful information requires understanding clinical intent, not simply moving data between systems. A system that reads a chart differently from how a clinician would is not integrated; it is connected. Connection and integration are not the same thing.
Dover's recommendation for CIOs and CMIOs is to treat integration as a core purchasing requirement, not something to address after signing a contract. Ask vendors to prove integration in your environment, with your data and your workflows, before committing.
Additionally, evaluate where the operational burden lies and choose a vendor that can deliver trustworthy information directly into existing workflows rather than forcing internal teams to figure it out.
The Ownership Gap That Stalls Promising Projects
Clinical leaders now most frequently own AI strategy, more often than IT organizations or executive leadership. That shift signals something important: healthcare AI is no longer being treated as a technology experiment. It is being treated as a clinical decision with clinical consequences.
At the same time, 26% of respondents reported having no clearly defined AI owner. A pilot without an owner loses momentum once the initial enthusiasm fades.
IT should own integration, security, and infrastructure. Executive leadership should maintain control over funding and oversight. Ownership of outcomes, however, should fall to a clinical leader.
What Vendors Are Being Evaluated On
The survey's strongest consensus involves vendor evaluation. Ninety-two percent of respondents said it’s critical for AI vendors to have deep expertise in the healthcare industry.
On its own, generic AI doesn’t distinguish between a case that is documented cleanly and one that is clinically ambiguous. That distinction matters enormously in practice, and it is the distinction that separates a system that performs well in a pilot from one that is trustworthy in a clinical setting.
Dover recommends examining whether vendors understand clinical workflows, can demonstrate measurable outcomes at peer organizations, and are willing to share performance risk rather than relying on successful pilot projects alone.
The Missing Layer
The Carta survey findings, taken together, describe a missing layer that sits between AI capability and clinical practice. The technology layer is increasingly capable. The missing layer is operational: workflow integration, governance, clinical domain expertise, and outcome measurement built in from the start.
For health systems building the evaluation and benchmarking infrastructure that makes this kind of deployment defensible, Taazaa's guide to benchmarking healthcare AI before deployment covers the reliability-first framework that leads to production-ready systems.
Turning Pilots into Scalable Solutions
The health systems that successfully scale AI share three characteristics.
1. They treat integration as a prerequisite, not a feature. Integration is specified as a purchasing requirement before any contract is signed. Vendors are required to demonstrate integration in the buyer's environment, with the buyer's data and workflows, before commitment.
2. They establish clear ownership before deployment begins. A named clinical leader is accountable for AI strategy and outcomes. IT owns integration, security, and infrastructure. Executive leadership owns funding and oversight.
3. They evaluate vendors on demonstrated outcomes, not demonstrations. Peer-validated results, willingness to share performance risk, and clinical domain expertise matter more than product features and demo performance.
For health systems working through what a comprehensive agentic AI program in healthcare looks like in practice, Taazaa's guide to agentic AI in healthcare covers the use cases, governance requirements, and implementation discipline that distinguish agentic deployments that compound in value from those that stall.
The Operational Question
Healthcare AI has proven it can work in contained pilot environments. The question that remains is whether healthcare organizations can build the operational layer that makes AI work at scale.
That operational layer requires clinical leadership with genuine accountability, integration that fits into existing workflows rather than interrupting them, and vendors who can demonstrate results in environments that resemble yours, rather than controlled conditions that do not.
To ensure the success of your next healthcare AI initiative, contact the experts at Taazaa. We have a depth of experience in both the healthcare industry and making AI operational at scale.
Frequently Asked Questions
Why do healthcare AI pilots succeed but fail to scale?
Pilots succeed because they are narrow, well-resourced, and championed. When organizations attempt to expand them, those conditions disappear. The Carta Healthcare survey found 71% of organizations with measurable AI value are still not expanding at pace, not because the technology failed, but because the operational layer was never built.
What is the leading barrier to healthcare AI adoption in 2026?
EHR integration difficulty was cited by 44% of respondents in the Carta Healthcare August 2026 survey as the leading barrier to AI adoption. It surpasses clinician trust and regulatory concerns as the primary obstacle to scaling AI in clinical environments.
Who should own the healthcare AI strategy?
A healthcare organization’s AI strategy should reside with a named clinical leader, not a committee or shared responsibility. Clinical leaders now most frequently own the AI strategy in health systems. IT should own its integration and infrastructure. Executive leadership should own funding and oversight. One clinical leader must remain accountable for outcomes.
What should healthcare organizations ask AI vendors before signing a contract?
Organizations should ask vendors to demonstrate integration with the organization’s environment, data, and workflows before committing. Evaluate whether they understand clinical workflows, can demonstrate measurable outcomes at peer organizations, and are willing to share performance risk.
